{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:30:48Z","timestamp":1792773048437,"version":"4.5.0"},"reference-count":107,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2016,8,2]]},"DOI":"10.3109\/10428194.2016.1160082","type":"journal-article","created":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T03:43:19Z","timestamp":1461728599000},"page":"1755-1765","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":37,"title":["Use of class I histone deacetylase inhibitor romidepsin in combination regimens"],"prefix":"10.3109","volume":"57","author":[{"given":"Adam","family":"Petrich","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, The University of Chicago","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-090711-163818"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.02.005"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.09.003"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/epi.3.3.6253"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(02)86002-X"},{"key":"e_1_3_2_8_1","unstructured":"ISTODAX (romidepsin) [package insert]. Summit NJ: Celgene Corporation; 2014. [cited 2016 Apr 15]. Available from: http:\/\/www.istodax.com\/wp-content\/uploads\/ISTODAX_PackageInsert.pdf."},{"key":"e_1_3_2_9_1","unstructured":"Zolinza (vorinostat) [package insert]. Whitehouse Station NJ: Merck & Co Inc; 2015. [cited 2016 Apr 15]. Available from: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zolinza\/zolinza_pi.pdf."},{"key":"e_1_3_2_10_1","unstructured":"Beleodaq (belinostat) [package insert]. Irvine CA: Spectrum Pharmaceuticals; 2014. [cited 2016 Apr 15]. Available from: http:\/\/www.sppirx.com\/downloads\/140703_final-beleodaq-pi-pt-info.pdf."},{"key":"e_1_3_2_11_1","unstructured":"Farydak (panobinostat) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corp; 2016. [cited 2016 Apr 15]. Available from: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/farydak.pdf."},{"key":"e_1_3_2_12_1","unstructured":"NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas V.2.2016. [cited 2016 Apr 15]. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3282ce6f8f"},{"key":"e_1_3_2_15_1","article-title":"Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment.","volume":"120","author":"Foss FM","year":"2012","unstructured":"Foss FM , Carson KR , Pinter-Brown L , et\u00a0al . Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment. Blood. 2012; 120:Abstract 1614.","journal-title":"Blood"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.049"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1548-5315(11)70414-4"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-202895"},{"key":"e_1_3_2_20_1","first-page":"566","article-title":"Treatment of cutaneous T-cell lymphoma\/mycosis fungoides.","volume":"18","author":"Parker SR","year":"2006","unstructured":"Parker SR , Bradley B. Treatment of cutaneous T-cell lymphoma\/mycosis fungoides. Dermatol Nurs. 2006; 18: 566\u2013570, 573\u2013575. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17286158.","journal-title":"Dermatol Nurs"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"e_1_3_2_22_1","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.","volume":"8","author":"Sandor V","year":"2002","unstructured":"Sandor V , Bakke S , Robey RW , et\u00a0al . Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002; 8: 718\u2013728.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2865"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1359-4117.2002.01039.x"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6150"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"e_1_3_2_29_1","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL).","volume":"124","author":"Pro B","year":"2014","unstructured":"Pro B , Horwitz SM , Prince HM , et\u00a0al . Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). Blood. 2014; 124:Abstract 1742.","journal-title":"Blood"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.711829"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-16"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C510"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2095"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3709.3709","article-title":"Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin.","volume":"114","author":"Cabell C","year":"2009","unstructured":"Cabell C , Bates S , Piekarz R , et\u00a0al . Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009; 114:Abstract 3709.","journal-title":"Blood"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.467"},{"key":"e_1_3_2_37_1","unstructured":"Folotyn (pralatrexate injection) [package insert]. Westminster CO: Allos Therapeutics Inc; 2012. [cited 2016 Apr 15]. Available from: http:\/\/www.folotyn.com\/downloads\/2012_05_folotyn_FPI.pdf."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2249"},{"key":"e_1_3_2_39_1","unstructured":"Revlimid (lenalidomide) [package insert]. Summit NJ: Celgene Corporation; 2015. [cited 2016 Apr 15]. Available from: http:\/\/www.revlimid.com\/wp-content\/uploads\/full-prescribing-information.pdf."},{"key":"e_1_3_2_40_1","article-title":"Results from a phase II study of lenalidomide oral monotherapy in relapsed\/refractory indolent non-Hodgkin\u2019s lymphoma.","volume":"110","author":"Witzig TE","year":"2007","unstructured":"Witzig TE , Vose JM , Moore TD , et\u00a0al . Results from a phase II study of lenalidomide oral monotherapy in relapsed\/refractory indolent non-Hodgkin\u2019s lymphoma. Blood. 2007; 110:Abstract 2560.","journal-title":"Blood"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1778.1778","article-title":"Romidepsin synergizes with lenalidomide in T cell lymphoma cell lines by increasing reactive oxygen species and modulating PI3K\/AKT and MAPK\/ERK signaling pathways.","volume":"124","author":"Cosenza M","year":"2014","unstructured":"Cosenza M , Civallero M , Fiorcari S , et\u00a0al . Romidepsin synergizes with lenalidomide in T cell lymphoma cell lines by increasing reactive oxygen species and modulating PI3K\/AKT and MAPK\/ERK signaling pathways. Blood. 2014; 124:Abstract 1778.","journal-title":"Blood"},{"key":"e_1_3_2_44_1","article-title":"Romidepsin and lenalidomide show a synergistic effect in T-cell lymphoma cell lines.","volume":"122","author":"Cosenza M","unstructured":"Cosenza M , Civallero M , Fiorcari S , et\u00a0al . Romidepsin and lenalidomide show a synergistic effect in T-cell lymphoma cell lines. Blood. 213:122:Abstract 5148.","journal-title":"Blood"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8582","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relaped\/refractory lymphoma and myeloma: phase 1 results.","volume":"32","author":"Lunning MA","year":"2014","unstructured":"Lunning MA , Ruan J , Nair S , et\u00a0al . A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relaped\/refractory lymphoma and myeloma: phase 1 results. J Clin Oncol. 2014; 32:Abstract 8582.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_46_1","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma.","volume":"33","author":"Mehta-Shah N","year":"2015","unstructured":"Mehta-Shah N , Lunning MA , Ruan J , et\u00a0al . A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma. Hematol Oncol. 2015; 33:Abstract 016.","journal-title":"Hematol Oncol"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2221"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.157"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.95.95","article-title":"Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL).","volume":"118","author":"Friedberg J","year":"2011","unstructured":"Friedberg J , Mahadevan D , Jung J , et\u00a0al . Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Blood. 2011; 118:Abstract 95.","journal-title":"Blood."},{"key":"e_1_3_2_51_1","article-title":"U.S. intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).","volume":"5","author":"Barr PM","year":"2014","unstructured":"Barr PM , Li H , Spier CM , et\u00a0al . U.S. intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). J Clin Oncol. 2014; 5s:Abstract 8523.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_52_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4493.4493","article-title":"The investigational aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin.","volume":"124","author":"Zullo K","year":"2014","unstructured":"Zullo K , Guo Y , Cooke L , et\u00a0al . The investigational aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin. Blood. 2014; 124:Abstract 4493.","journal-title":"Blood"},{"key":"e_1_3_2_53_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1744.1744","article-title":"A phase I trial of alisertib plus romidepsin for relapsed\/refractroy aggressive B- and T-cell lymphomas.","volume":"124","author":"Fanale MA","year":"2014","unstructured":"Fanale MA , Hagemeister FB , Fayad L , et\u00a0al . A phase I trial of alisertib plus romidepsin for relapsed\/refractroy aggressive B- and T-cell lymphomas. Blood. 2014; 124:Abstract 1744.","journal-title":"Blood"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/5047"},{"key":"e_1_3_2_55_1","first-page":"7089","article-title":"Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.","volume":"63","author":"Belinsky SA","year":"2003","unstructured":"Belinsky SA , Klinge DM , Stidley CA , et\u00a0al . Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003; 63: 7089\u20137093.","journal-title":"Cancer Res"},{"key":"e_1_3_2_56_1","unstructured":"Dacogen (decitabine) [package insert]. Dublin CA: Astex Pharmaceuticals Inc; 2014. [cited 2016 Apr 15]. Available from: http:\/\/otsuka-us.com\/products\/Documents\/DACOGEN.PI.pdf."},{"key":"e_1_3_2_57_1","first-page":"1327","article-title":"DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.","volume":"61","author":"Zhu WG","year":"2001","unstructured":"Zhu WG , Lakshmanan RR , Beal MD , et\u00a0al . DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001; 61: 1327\u20131333.","journal-title":"Cancer Res"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402776"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00222-9"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336891"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13566"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01799-07"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00011"},{"key":"e_1_3_2_64_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)15093-1","article-title":"Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo.","volume":"26","author":"Lu LJ","year":"1984","unstructured":"Lu LJ , Randerath K. Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo. Mol Pharmacol. 1984; 26: 594\u2013603.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_3_2_66_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.tps8616","article-title":"ROCHOP study: a phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.","volume":"31","author":"Delarue R","year":"2013","unstructured":"Delarue R , Zinzani PL , Hertzberg MS , et\u00a0al . ROCHOP study: a phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma. J Clin Oncol. 2013; 31:Abstract TPS8616.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg702"},{"key":"e_1_3_2_68_1","first-page":"124:","article-title":"Phase I study of romidepsin in combination with ICE (ifosfamide, carboplatin, and etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma.","author":"Chihara D","year":"2014","unstructured":"Chihara D , Oki Y , Fayad L , et\u00a0al . Phase I study of romidepsin in combination with ICE (ifosfamide, carboplatin, and etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2014; 124:Abstract 1748.","journal-title":"Blood"},{"key":"e_1_3_2_69_1","unstructured":"Velcade (bortezomib) [package insert]. Cambridge MA: Millennium Pharmaceuticals Inc; 2015. [cited 2016 Apr 15]. Available from: http:\/\/www.velcade.com\/files\/pdfs\/velcade_prescribing_information.pdf."},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04882.x"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016055"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0561"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1159\/000089471"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235663"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339879"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-110445"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22097"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150227"},{"key":"e_1_3_2_79_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V94.4.1401","article-title":"Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.","volume":"94","author":"Byrd JC","year":"1999","unstructured":"Byrd JC , Shinn C , Ravi R , et\u00a0al . Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 1999; 94: 1401\u20131408.","journal-title":"Blood"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3794"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1693"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1934"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207"},{"key":"e_1_3_2_84_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1587.1587","article-title":"The histone deacetylase inhibitor vorinostat induces apoptosis in T-cell lymphoma cell lines and synergizes with bortezomib","volume":"112","author":"Cultrera JL","year":"2008","unstructured":"Cultrera JL , Rosenberg L , McConkey DJ , et\u00a0al . The histone deacetylase inhibitor vorinostat induces apoptosis in T-cell lymphoma cell lines and synergizes with bortezomib. Blood. 2008; 112:Abstract 1587.","journal-title":"Blood"},{"key":"e_1_3_2_85_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3050.3050","article-title":"Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: updated results","volume":"124","author":"Holkova B","year":"2014","unstructured":"Holkova B , Kmieciak M , Bose P , et\u00a0al. Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: updated results. Blood. 2014; 124:Abstract 3050.","journal-title":"Blood"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130281"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10905.x"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2012.675382"},{"key":"e_1_3_2_89_1","unstructured":"Gemzar (gemcitabine for injection) [package insert]. Indianapolis IN: Lilly USA; 2014. [cited 2016 Apr 15]. Available from: http:\/\/pi.lilly.com\/us\/gemzar.pdf."},{"key":"e_1_3_2_90_1","first-page":"679","article-title":"FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.","volume":"24","author":"Sato N","year":"2004","unstructured":"Sato N , Ohta T , Kitagawa H , et\u00a0al . FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol. 2004; 24: 679\u2013685.","journal-title":"Int J Oncol"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006091014092"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.9.1911"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2006.12.012"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318046eedc"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2007.06.002"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.5.4007"},{"key":"e_1_3_2_97_1","first-page":"900","article-title":"In vivo evaluation of depsipeptide (FK228) alone or in combination with gemcitabine in two human pancreas tumor xenograft models.","volume":"66","author":"Lowell W","year":"2006","unstructured":"Lowell W , Wick MJ , Campos DR , et\u00a0al . In vivo evaluation of depsipeptide (FK228) alone or in combination with gemcitabine in two human pancreas tumor xenograft models. Proc Amer Assoc Cancer Res. 2006; 66: 900\u2013901.","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"e_1_3_2_98_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8088","article-title":"Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC).","volume":"31","author":"Gerber DE","year":"2013","unstructured":"Gerber DE , Skelton R , Dong Y , et\u00a0al . Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013; 31:Abstract 8088.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0555"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318194fae7"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(24)12311-5"},{"key":"e_1_3_2_102_1","first-page":"2583","article-title":"The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.","volume":"61","author":"Cartee L","year":"2001","unstructured":"Cartee L , Wang Z , Decker RH , et\u00a0al . The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res. 2001; 61: 2583\u20132591.","journal-title":"Cancer Res"},{"key":"e_1_3_2_103_1","first-page":"2885","article-title":"Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.","volume":"4","author":"Schrump DS","year":"1998","unstructured":"Schrump DS , Matthews W , Chen GA , et\u00a0al . Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 1998; 4: 2885\u20132890.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2003.180"},{"key":"e_1_3_2_105_1","unstructured":"Abraxane (paclitaxel protein-bound particles for injectable suspension) [package insert]. Summit NJ: Celgene Corporation; 2015. [cited 2016 Apr 15]. Available from: http:\/\/www.abraxane.com\/wp-content\/uploads\/Abraxane_Prescribing_Information.pdf."},{"key":"e_1_3_2_106_1","first-page":"219","article-title":"The class I HDAC inhibitor romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.","volume":"10","author":"Robertson FM","year":"2013","unstructured":"Robertson FM , Chu K , Boley KM , et\u00a0al . The class I HDAC inhibitor romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. J Exp Ther Oncol. 2013; 10: 219\u2013233.","journal-title":"J Exp Ther Oncol"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4725"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.09.016"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tandfonline.com\/doi\/pdf\/10.3109\/10428194.2016.1160082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2016.1160082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.3109\/10428194.2016.1160082","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2016.1160082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:09:25Z","timestamp":1792764565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428194.2016.1160082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8,2]]}},"alternative-id":["10.3109\/10428194.2016.1160082"],"URL":"https:\/\/doi.org\/10.3109\/10428194.2016.1160082","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}